Future Advances of Immunotherapy
Allergen immunotherapy, although effective, has been, to a degree, displaced by symptomatic therapy for bronchial asthma and allergic rhinitis. A major reason for its loss of popularity is the prolonged course of the treatment and the occurrence of reactions, both of which are due to the reaction of the allergenic extract with IgE. Thanks to recombinant technology, the possibility exists of modifying the major allergens so that they have reduced reactivity with IgE. Furthermore, the recombinant allergens can be combined with immunostimulatory sequences that favor the transformation from the Th2 phenotype characteristic of allergy to a Th1 cytokine profile. Thus, recombinant technology and new understanding of ways to alter the immune response to allergens promises to make allergy immunotherapy safer and more efficient.
Document Type: Regular Paper
Publication date: 01 July 2001
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service. - Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Commercial level: Permission to use content
- www.JFoodAllergy.com
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content